Audit: QRS - Vegan Diet for Health & Longevity

Audit conducted on 10/30/2026 07:26 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	97
Passed	86
Failed	0
N/A	11
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Lede, Protocol, Time to effect, gates, tiers, Monitoring and Qualitative items each trace to ER text (Conclusion, Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks, Key Interactions & Contraindications, Monitoring Protocol).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	ER hedges kept: “(not studied in this group)”, “(no controlled human data)”, “(no vegan-specific human data)”; lede keeps “lifespan effects remain uncertain”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening found; lede “reliably lowers” matches ER Conclusion.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefits, risks, contraindications and interactions each sit under their ER category.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only “Gardner, Stanford” and “twin trial” appear, both in the ER for the same protocol fact; no PMIDs, NCT IDs or brands.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is expert, accessible, objective, and data-driven	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses the reader directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Jargon limited to ER labels carried verbatim (sulfonylureas, ACE inhibitors and ARBs) and marker names/thresholds.
2.8	Information is presented in a concise and very compact manner	🟢
2.9	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.10	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.11	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.13	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.14	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No consumer-grade route or dosage terms found.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” Gate headings: “Contraindications”, “Key Interactions” Tier labels: “High”, “Medium”, “Low”, “Speculative” Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, tier labels and column headers unchanged (lines 446, 483, 525, 545, 557, 590, 609, 613-615, 805).
3.2	Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name	🟢	All template data-qrs-var names present; marker_# and qualitative_item_# expanded to 1..16 and 1..6.
3.3	Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well	🟢	Source diff against template shows changes only inside spans, in the metadata block, and the repeated marker/qualitative rows; risks_high hidden per 13.5.

4. Formatting

#	Description	Result	Comments
4.1	An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over.	🟢	Empty High risk tier hidden (line 592); “Not specified in the ER” used only as required by 14.3.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit.	🟢	No trailing dash clauses, glosses removed from labels, example lists trimmed, no repeated items.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	duration is quoted because it contains a colon; other values unquoted and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model	🟢	“Opus 5.5” consistent with the naming rule.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-1030-0656 -> 10/30/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “A vegan diet, an animal-free eating pattern for health and longevity”.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	69 words (script count).
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER populations listed (lines 548-552).
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation inside parens in its contraindications.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found	🟢	Five documented interactions listed (lines 560-564).
9.3	[caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label	🟢	Six theoretical interactions listed (lines 574-579).
9.4	The ER placeholder “None identified” is never an item: it means that group is empty	🟢
9.5	Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause	🟢
9.6	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.7	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
9.8	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation inside parens in its interactions.
9.9	If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER theoretical group has six items; block is shown.
9.10	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.11	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g.	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Therapeutic Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from that section	🟢	Diet pattern (Gardner whole-food), core supplements, protein target.
10.3	If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	ER Therapeutic Protocol names more than three actionable aspects; all three sets used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	All three tie to High-tier benefits, ordered as the ER ranks them (weight, LDL, glycemic control).
11.3	If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing.	N/A	ER gives three time-to-effect aspects (LDL, weight, HbA1c); all sets used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty.	N/A	ER Practical Considerations gives time to effect.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high has no items and is hidden with style=”display:none” (line 592).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
14.2	All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names	🟢	16 rows cover all markers named in the section (ER table rows plus CBC, iodine, weight, blood pressure, glucose).
14.3	[marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER”	🟢	Targets match ER table; urinary iodine 100-200 µg/L from ER risk section; missing targets read “Not specified in the ER”.
14.4	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty.	🟢
14.5	If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template	N/A	ER names measurable biomarkers; table is populated.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring Protocol & Defining Success section	🟢
15.2	All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 …	🟢	Six ER qualitative markers listed verbatim (lines 807-824).
15.3	If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template	N/A	ER names six qualitative markers; list is populated.

Issues 10/30/2026 07:26

Pass rate 100.00%. No issues found.

Issues 10/30/2026 07:21

1. 14.2 — Complete blood count missing: The ER Monitoring table pairs ferritin with a complete blood count (ER line 456), but the QRS Monitoring table (lines 619-783) has no row for it.

Fixes 10/30/2026 07:21

1. 14.2 — Complete blood count added: Added a Monitoring row “Complete blood count” (target “Not specified in the ER”, why “Paired with ferritin”) after Ferritin and renumbered the following marker variables 5-15 to 6-16.

Issues 10/30/2026 07:18

1. 1.2 — Contraindication hedges dropped: The gate items at lines 549, 551 and 552 omit the ER’s cautious phrasing for inferred contraindications (“not studied in this group”, “no controlled human data”, “no vegan-specific human data”, ER lines 360, 362, 363), presenting them as established.

Fixes 10/30/2026 07:18

1. 1.2 — Contraindication hedges restored: Added the ER’s cautious phrasing to three gate items: “(not studied in this group)” to the osteoporosis item, “(no controlled human data)” to the eating-disorder item, and “; no vegan-specific human data” inside the kidney-disease parenthetical.

Issues 10/30/2026 07:16

1. 4.5 — Untrimmed list and repetition: The theoretical supplements item at line 579 keeps all four examples “(red yeast rice, plant sterols, psyllium, berberine)”, and time_3_sub at line 517 repeats the 8–12 week HbA1c retest timing already given in the cadence at line 788.

Fixes 10/30/2026 07:16

1. 4.5 — Trimmed list, removed repetition: Trimmed the theoretical supplements label to “(red yeast rice, berberine)” and replaced time_3_sub “Reflects about 3 months, so retesting comes no sooner than 8–12 weeks” with the ER’s “Largely through weight loss and better insulin sensitivity”.

Issues 10/30/2026 07:13

1. 2.7 — Clinical term “titrated”: action_2_sub (line 467) reads “algal omega-3 titrated to an omega-3 index of 8% or more”; the ER’s own plain wording “adjusted toward” is available.
2. 9.7 — Time window dropped: The acid-suppressant interaction (line 578) omits the ER’s “two or more years of use”, the duration that determines whether the raised B12 deficiency odds apply.

Fixes 10/30/2026 07:13

1. 2.7 — Clinical term replaced: In action_2_sub, changed “algal omega-3 titrated to an omega-3 index” to the ER’s own wording “algal omega-3 adjusted toward an omega-3 index”.
2. 9.7 — Time window restored: Appended “after two or more years of use” to the acid-suppressant interaction, matching the ER’s duration qualifier.

Issues 10/30/2026 07:10

1. 4.5 — Untrimmed example drug lists: Five Key Interactions items keep two example drugs each on an over-full sheet: “(e.g., glipizide, glyburide)” line 560, “(e.g., spironolactone, eplerenone)” line 564, “(e.g., amlodipine, lisinopril)” line 574, “(e.g., lisinopril, losartan)” line 575, “(e.g., atorvastatin, rosuvastatin)” line 576.

Fixes 10/30/2026 07:10

1. 4.5 — Example drug lists trimmed: Cut five Key Interactions example lists to one drug each: glipizide, spironolactone, amlodipine, lisinopril and atorvastatin (dropped glyburide, eplerenone, the repeated lisinopril, losartan and rosuvastatin).

Issues 10/30/2026 07:04

1. 2.5 / 2.6 — Imperatives address the reader: time_3_sub at line 517 says “retest no sooner than 8–12 weeks” and marker_15_target at line 778 says “track change from own baseline”, both directives rather than presented information.
2. 14.3 — Iodine target misreported: marker_7 at lines 687–693 is “Iodine” / “Not specified in the ER”, but the ER gives urinary iodine with a World Health Organization optimum of 100–200 µg/L.

Fixes 10/30/2026 07:04

1. 2.5 / 2.6 — Imperatives address the reader: Changed time_3_sub from “retest no sooner than 8–12 weeks” to “so retesting comes no sooner than 8–12 weeks”, and marker_15_target from “track change from own baseline” to “change tracked from the individual’s own baseline” (ER wording).
2. 14.3 — Iodine target misreported: Renamed marker_7 from “Iodine” to “Urinary iodine” and replaced “Not specified in the ER” with the ER’s WHO optimum “100–200 µg/L”.

Issues 10/30/2026 07:01

1. 1.3 — Fracture claim generalized in lede: The at-a-glance at line 439 says “hip fractures are more frequent, less so with enough calcium and vitamin D”, generalizing the ER Conclusion’s “vegans in two large studies had more hip fractures, a pattern that weakened or disappeared with enough calcium and vitamin D”.
2. 9.5 / 9.6 — Mechanism clause in theoretical items: The acid-suppressant (line 578) and cholesterol-/glucose-lowering supplement (line 579) items carry the ER’s “Inferred from” mechanism (“additive vitamin B12 depletion”; “additive LDL or glucose lowering”) instead of the ER’s stated consequence.

Fixes 10/30/2026 07:01

1. 1.3 — Fracture claim in lede: Replaced “hip fractures are more frequent, less so with enough calcium and vitamin D” with “two large studies found more hip fractures, weakening or disappearing with enough calcium and vitamin D”, matching the ER Conclusion; also cut “followed” and “in people” to keep the lede within 70 words.
2. 9.5 / 9.6 — Mechanism clauses replaced: Changed the acid-suppressant item from “additive vitamin B12 depletion” to “raised vitamin B12 deficiency odds”, and the supplements item from “additive LDL or glucose lowering” to “possible low blood sugar when berberine is combined with diabetes drugs”.

Issues 10/30/2026 06:59

1. 1.2 / 1.3 — Lede drops nutrient hedge: The At-A-Glance at line 439 writes “iodine, calcium, vitamin D and fish-type omega-3 fats run low”, dropping the ER Conclusion’s cautious “tend to run low”.
2. 4.5 — Time-to-effect repetition: time_2_sub at line 506 “LDL fell within 8 weeks in the twin trial” repeats the label and the value “Within 8 weeks” above it.
3. 14.2 — Glucose marker missing: The ER Monitoring section (ER line 447) names glucose alongside blood pressure and lipids for tracking drug adjustments; the table has a Blood pressure row but no glucose row.

Fixes 10/30/2026 06:59

1. 1.2 / 1.3 — Restored nutrient hedge: Changed the lede’s “fish-type omega-3 fats run low” to “tend to run low”, matching the ER Conclusion, and condensed “an eating pattern without animal foods” to “an animal-free eating pattern” to keep the lede at 69 words.
2. 4.5 — Removed time-to-effect repetition: Changed time_2_sub from “LDL fell within 8 weeks in the twin trial” to “As seen in the twin trial”.
3. 14.2 — Added glucose marker: Added a Glucose row (target “Not specified in the ER”, why “Tracks drug adjustments”) as marker_13 and renumbered Omega-3 index and Bone mineral density to marker_14 and marker_15.